Axsome Therapeutics (AXSM) Accounts Payables (2015 - 2026)

Axsome Therapeutics' Accounts Payables history runs 12 years deep, the most recent figure standing at $106.7 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 24.57% year-over-year to $106.7 million; the TTM figure through Mar 2026 stood at $106.7 million (up 24.57% YoY), while the FY2025 annual figure was $65.5 million, down 55.71% from the prior year.
• Accounts Payables came in at $106.7 million for Q1 2026 at Axsome Therapeutics, up from $65.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $148.0 million in Q4 2024 to a low of $12.6 million in Q1 2022.
• A 5-year average of $66.5 million and a median of $64.3 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables soared 510.79% in 2023 and slumped 55.71% in 2025, its largest moves.
• Axsome Therapeutics' Accounts Payables stood at $51.6 million in 2022, then jumped by 75.28% to $90.5 million in 2023, then jumped by 63.52% to $148.0 million in 2024, then tumbled by 55.71% to $65.5 million in 2025, then soared by 62.81% to $106.7 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $106.7 million, $65.5 million, and $54.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison